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Abstract
Background COVID-19 has caused considerable morbidity and mortality worldwide and cardiac involvement has been 
reported during infection. The short-term cardiac outcome in survivors of COVID-19 is not known.
Objective To examine the heart of patients who survived COVID-19 and to compare the cardiac outcome between patients 
who recovered from mild-to-moderate or severe illness.
Methods With use of ECG and echocardiography, we examined the heart of 105 patients who had been hospitalized with 
COVID-19 and were consecutively recruited after hospital discharge while attending follow-up visits. Survivors of COVID-
19 were compared with 105 matched controls. We also compared the cardiac outcome and lung ultrasound scan between 
COVID-19 patients who had mild-to-moderate or severe illness.
Results Cardiac data were collected a median of 41 days from the first detection of COVID-19. Symptoms were present in a 
low percentage of patients. In comparison with matched controls, no considerable structural or functional differences were 
observed in the heart of survivors of COVID-19. Lung ultrasound scan detected significantly greater residual pulmonary 
involvement in COVID-19 patients who had recovered from severe than mild-to-moderate illness. No significant differences 
were detected in ECG tracings nor were found in the left and right ventricular function of patients who had recovered from 
mild-to-moderate or severe illness.
Conclusions In a short-term follow-up, no abnormalities were identified in the heart of survivors of COVID-19, nor cardiac 
differences were detected between patients who had different severity of illness. With the limitations of a cross-sectional 
study, these findings suggest that patients who recover from COVID-19 do not have considerable cardiac sequelae.
Supplementary Information The online version contains 
supplementary material available at https ://doi.org/10.1007/s0039 
2-020-01800 -z.
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Introduction
The dreadful pandemic caused by Severe Acute Respira-
tory Syndrome-Coronavirus-2 (SARS-CoV-2) represents 
an unprecedented challenge for the healthcare community 
and has already left behind thousands of victims worldwide. 
High infectivity and ability to be transmitted even by asymp-
tomatic subjects have resulted in a rapid spread of infection 
throughout all continents, causing a disease that has been 
named coronavirus disease 2019 (COVID-19) [1]. COVID-
19 involves primarily the respiratory system, presenting with 
a broad range of clinical pictures, from a very mild flulike 
illness to fatal acute respiratory distress syndrome (ARDS) 
[2]. Notably, additional cardiac, vascular, gastrointestinal, 
renal, hepatic, and neurologic involvement has been reported 
in COVID-19 patients [3], supporting the tenet of a systemic 
spread of the virus.
The COVID-19 outbreak has triggered an explosion of 
clinical and experimental research which has already pro-
vided important insights into the pathogenesis of this infec-
tion and its complications. Many reports from geographical 
areas that have endured the heaviest burden of deaths caused 
by COVID-19 have provided evidence that older age and 
preexisting cardiovascular conditions enhance vulnerability 
of patients to infection [4]. On the other hand, studies preva-
lently conducted in China where the outbreak originated, 
indicated cardiac injury as a prominent feature complicating 
the course of COVID-19 [5]. Cardiac involvement was in 
fact demonstrated in a substantial proportion of patients with 
COVID-19 by detection of increased levels of biochemical 
markers such as troponins and brain-type natriuretic peptide 
and was associated with elevated mortality [6, 7]. Mecha-
nisms of cardiac injury in COVID-19 are not clear, but might 
involve direct cardiac localization of virus, myocardial stress 
due to hypoxemia caused by respiratory failure, indirect 
injury linked to systemic inflammatory response causing an 
uncontrollable cytokine storm, or a combination of them [8].
Despite high infectivity, SARS-CoV-2 virulence is mild 
with a relatively low fatality rate [9, 10]. Consequently, 
the majority of patients survive COVID-19 leaving open 
an important question about the possible organ sequelae of 
infection. Because the heart has been reported to be critically 
involved in COVID-19, we undertook a study to investigate 
the short-term cardiac outcome of patients who recovered 
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from disease. By the use of cardiac ultrasound, we examined 
the structure and function of the heart of patients who had 
been hospitalized with COVID-19 and compared the cardiac 
characteristics of patients who recovered from mild-to-mod-
erate or severe illness. We also examined the association of 
cardiac characteristics with biochemical markers that were 
measured during the acute phase of infection.
Methods
Study design, setting, and participants
This observational study was conducted at the University 
Hospital-University of Udine, a quaternary acute care 
regional hospital serving an area of more than 700,000 peo-
ple in northeast of Italy. We examined the cardiac structure 
and function by echocardiography in consecutive COVID-19 
patients that attended the dedicated outpatient Clinic after 
hospital discharge, from April 15 to May 15, 2020. From 
March 15 to April 15, 2020, patients had presented with 
fever and/or respiratory symptoms at specific COVID-19 
points of care that were set up in the Infectious Disease and 
the Emergency Units of the Hospital and had positive test 
results for the SARS-CoV-2 on a nasopharyngeal swab. 
Tests were conducted with a reverse-transcriptase-polymer-
ase-chain-reaction (RT-PCR) by the Central Laboratory of 
the Hospital that serves as a facility for SARS-CoV-2 detec-
tion in the whole area and COVID-19 was diagnosed on the 
basis of the World Health Organization guidance [11]. All 
patients with a positive test result for SARS-CoV-2 were 
assessed according to a clinical severity score (Supplemen-
tary Table 1). The score was specifically developed for the 
COVID-19 outbreak by the Italian Society of Emergency 
Medicine by setting five levels [12] that incorporate all the 
criteria that are currently used to define severity of illness 
[9]. Depending upon the severity score, patients were admit-
ted either to a COVID-19 isolation unit for close monitoring 
of clinical progression and oxygen support with high-flow 
nasal cannula (level 1 and level 2), a COVID-19 isolation 
sub-intensive care unit for oxygen support with continuous 
positive airway pressure (level 3), or a COVID-19 isolation 
intensive care unit for invasive mechanical ventilation with 
orotracheal intubation (level 4 and level 5). The severity 
score was reassessed after admission, and the highest level 
reached during hospitalization was considered for analysis. 
Patients within levels 1–2 were assigned to a mild-to-mod-
erate COVID-19 group and patients within levels 3–5 to 
a severe COVID-19 group. Survivors of COVID-19 were 
discharged from the Hospital with scheduled follow-up vis-
its, during which clinical variables were reassessed, naso-
pharyngeal swab was repeated, blood samples for labora-
tory tests were collected, and ECG, lung ultrasound, and 
echocardiography were performed. Patients who attended 
follow-up visits during that period were 61% of those who 
were discharged from March 15 to April 15, 2020, and there-
fore a selection bias cannot be excluded. The study complied 
with the Declaration of Helsinki and received approval from 
the Internal Review Board of the Department of Medicine 
under a fast-track review process. All patients gave their 
written informed consent to the study.
Data collection
Patients’ data were collected from the University Hospital 
electronic database. The database is continuously and timely 
updated and contains all the data of patients registered to the 
Hospital, including patients’ demographic, anthropometric, 
and clinical variables, laboratory test results, historical and 
current diagnoses together with history of previous hospi-
talizations, and historical and current medication list.
Control subjects
Cardiac ultrasound variables that were measured after hospi-
tal discharge in survivors of COVID-19 were compared with 
those of a control group of COVID-19 negative individuals. 
These individuals were selected by use of a nearest neighbor 
matching strategy from an internal database of subjects that 
are representative of the general population of the same geo-
graphical area of COVID-19 patients. The database contains 
demographic, anthropometric, and clinical data, laboratory 
test results, and cardiac ultrasound measurements of more 
than 1000 subjects who had consecutively attended the out-
patient service of the Internal Medicine and Cardiovascu-
lar Clinic of the University Hospital from January 2018 to 
December 2019. Exact matching was used to adjust for age, 
sex, and hypertension prevalence.
Echocardiography
We performed two-dimensional, Doppler, and tissue-Dop-
pler imaging (TDI) transthoracic echocardiography in survi-
vors of COVID-19 after hospital discharge. Examination was 
performed with use of appropriate personal protective equip-
ment [13] by experienced investigators who were blinded 
to the clinical and laboratory data, in accordance with the 
joint recommendations of the American Society of Echocar-
diography and the European Association of Cardiovascular 
Imaging [14], as described previously [15] (Supplementary 
methods). Measurements of left and right atrial volumes, 
left and right ventricular dimensions, left ventricular mass 
and geometry, and systolic pulmonary artery pressure were 
obtained by use of two-dimensional and Doppler ultrasound. 
Left and right ventricular systolic and diastolic function 
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were assessed by use of two-dimensional, Doppler, and TDI 
echocardiography.
Lung ultrasound
Lung ultrasound was performed by scanning two different 
areas in the anterior, lateral, and posterior region of each 
lung. A point score was obtained for each examined area as 
follows [16]: 0 points for A lines (normal visualization of the 
pleural lines with lung sliding that indicate normal lung aer-
ation); 1 point for B lines (shining lines perpendicular to the 
pleural space erasing A lines at the edge of the screen due 
to a reverberation artifact through edematous interlobular 
septa) that indicate moderate loss of lung aeration; 2 points 
for lung consolidation. Therefore, for each patient the lung 
ultrasound score was between 0 and 24 points.
Statistical analysis
Normality of variables distribution was assessed with the 
Shapiro–Wilk test. Normally distributed continuous vari-
ables are reported as mean ± standard deviation (SD) and 
skewed variables as median ± interquartile range (IQR). 
Independent sample Student’s t test was used for compari-
son between groups of normally distributed variables and 
the Mann–Whitney U test for comparison of skewed vari-
ables. Point differences between means or medians with 95% 
confidence intervals are reported together with P values. 
Categorical variables are reported as counts, and percent-
ages and differences are reported as percentage point with 
95% confidence intervals together with P values that were 
tested by use of the Fisher’s exact test. The primary analysis 
was an evaluation of cardiac ultrasound characteristics of 
patients who survived COVID-19 in a comparison with a 
control group of matched subjects and of COVID-19 patients 
who had recovered from mild-to-moderate or severe illness. 
Analyses were conducted using Stata software, version 12.1 
(StataCorp).
Results
Study patients and control subjects
From April 15 to May 15, 2020, 105 patients who were 
discharged from the hospital attended scheduled follow-up 
visits with ECG registration and heart and lung ultrasound 
examination. The date of COVID-19 diagnosis was con-
sidered as the index date to calculate the timing of cardiac 
ultrasound examination that was performed after a median 
of 41 days (IQR: 37–44 days). After hospital discharge, 
lymphocyte and platelets counts increased significantly 
(both P < 0.001) whereas serum levels of creatine kinase, 
lactate dehydrogenase, C-reactive protein, procalcitonin, and 
D-dimer decreased (all P < 0.001) (Supplementary Table 2). 
At follow-up, 25 (24%) of 105 COVID-19 patients still had 
positive test results for SARS-CoV-2 on the nasopharyngeal 
swab.
The demographic and clinical characteristics of COVID-
19 survivors and controls are shown in Supplementary 
Table 3. Body mass index and blood pressure were appro-
priately balanced in the two groups. A history of hyperten-
sion was present in 30% of study patients and controls and 
current smokers were 15% and 16%, respectively. All the 
additional coexisting conditions had a prevalence of less 
than 10% in patients and controls. Table 1 summarizes the 
echocardiographic variables of COVID-19 patients and con-
trols. Dimensions of the left and right heart chambers were 
comparable in COVID-19 survivors and controls and also 
left ventricular mass and relative wall thickness did not dif-
fer between the two groups. Left ventricular ejection frac-
tion and fractional shortening, mitral annular plane systolic 
excursion (MAPSE) and TDI peak systolic velocity (S’) val-
ues did not differ between COVID-19 survivors and controls. 
All markers of left ventricular diastolic function obtained 
by Doppler ultrasound (peak E velocity; E/A ratio; E wave 
deceleration time; tricuspid regurgitation peak velocity) 
and TDI (mitral annular e’ velocity; e’/a’ ratio; E/e’ ratio) 
were comparable between COVID-19 survivors and con-
trols. Variables of right ventricular systolic (right ventricular 
fractional shortening; tricuspid annular plane systolic excur-
sion; tricuspid annular peak systolic velocity) and diastolic 
(tricuspid annular e’ velocity and e’/a’ ratio) function also 
had comparable values in COVID-19 survivors and controls. 
The systolic pulmonary artery pressure was 22 mm Hg in 
both the study patients and controls. High-sensitivity serum 
troponin was measured at the time of echocardiographic 
assessment and was below the upper limit of normal values 
according to local hospital criteria as defined by the 99th 
percentile of healthy reference population (males 79 ng/l; 
females 54 ng/ml) in all patients (median 5 ng/l; IQR 1–13).
Patients with mild‑to‑moderate or severe COVID‑19
Of 105 study patients, 27 (26%) had been hospitalized with 
severe COVID-19 requiring mechanical ventilation with 
either continuous positive airway pressure or orotracheal 
intubation and the remaining 78 (74%) with mild-to-moder-
ate disease. Table 2 shows the clinical, and laboratory that 
were measured in the COVID-19 patients during hospitali-
zation. Male sex was more frequent (P = 0.012) in patients 
with severe (74%) than mild-to-moderate (46%) COVID-19. 
Patients with severe COVID-19 had lower lymphocyte count 
and higher median values of transaminases, lactate dehy-
drogenase, C-reactive protein, procalcitonin, D-dimer, and 
interleukin-6 than patients with mild-to-moderate COVID-19 
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(all P < 0.001). Drug treatments that were used in COVID-19 
patients during hospitalization are shown in Supplementary 
Table 4. Hydroxychlorochine (63% and 96%, respectively) and 
azithromycin (39% and 37%, respectively) were used most fre-
quently in both mild-to-moderate and severe COVID-19. The 
frequency of use of antiviral agents such as darunavir–cobi-
cistat and lopinavir/ritonavir in patients with severe COVID-
19 was twofold of patients with mild-to-moderate COVID-
19. Moreover, tocilizumab, an interleukin-6 antagonist, was 
used in a substantial proportion (56%) of patients with severe 
COVID-19. At follow-up, symptoms were present in a limited 
percentage of patients (Table 3) with no differences between 
those who recovered from mild-to-moderate or severe illness. 
ECG tracings showed also no significant differences between 
COVID-19 patients who had mild-to-moderate or severe ill-
ness. As shown in Table 4, left and right atrial and ventricular 
dimensions, left ventricular mass and relative wall thickness, 
markers of left and right ventricular systolic and diastolic 
Table 1  Cardiac ultrasound characteristics of survivors of COVID-19 and matched controls
Values are means (SD). The 95% confidence intervals (CI) have not been adjusted for multiple testing and should not be used to infer definitive 
effects. Cases of COVID-19 were diagnosed between March 15 and April 15, 2020. Controls were selected by use of a nearest neighbor match-
ing strategy from a large internal database of subjects that are representative of the general population and were exactly matched for age, sex, 
and hypertension, whereas propensity score models were used for matching of body mass index, smoking, diabetes mellitus, hyperlipidemia, 
coronary artery disease, congestive heart failure, atrial fibrillation, and chronic obstructive pulmonary disease
a Tissue-Doppler imaging variables. S’, peak systolic velocities were measured either at the mitral or tricuspid annulus with the Doppler beam 
directed parallel to the myocardial walls; e’, early-diastolic myocardial velocity was measured either at the mitral or tricuspid annulus; a’, late-
diastolic myocardial velocity was measured either at the mitral or tricuspid annulus
b E, early-wave trans-mitral peak velocity; A, late-wave trans-mitral peak velocity
c Measurement of tricuspid regurgitation peak velocity and calculation of systolic arterial pulmonary pressure could be performed in in 84.8% of 









 Left atrial volume—ml 42 (19) 40 (11) 2 (-1 to 6) 0.136
 Left ventricular end-diastolic diameter—mm 47 (6) 49 (5) -2 (-3 to 1) 0.060
 Left ventricular end-systolic diameter—mm 28 (6) 29 (6) − 1 (− 2 to 1) 0.158
 Interventricular septum—mm 9.1 (1.9) 9.0 (1.8) 0.1 (− 0.2 to 0.9) 0.557
 Posterior wall—mm 9.0 (1.8) 8.9 (1.6) 0.1 (− 0.3 to 0.9) 0.168
 Left ventricular mass index—g/m2.7 34.6 (10.7) 35.5 (10.6) − 0.9 (− 4.4 to 2.2) 0.572
 Relative wall thickness—% 0.386 (0.098) 0.369 (0.072) 0.017 (− 0.009 to 0.060) 0.117
 Left ventricular ejection fraction—% 68 (10) 69 (7) − 1 (− 4 to 1) 0.350
 Left ventricular fractional shortening—% 39.1 (7.1) 40.5 (9.8) − 1.4 (− 4.0 to 1.2) 0.293
 Mitral annular plane systolic excursion—mm 13.9 (2.4) 15.0 (2.6) − 1.1 (− 2.9 to 0.4) 0.264
 Mitral annular peak systolic velocity S’—cm/sa 9.2 (2.1) 8.2 (2.0) 1.0 (− 0.5 to 1.6) 0.097
 Peak E wave velocity—cm/s 74 (21) 71 (20) 3 (− 4 to 9) 0.822
 E/A  ratiob 1.24 (0.56) 1.27 (0.39) − 0.03 (− 0.22 to 0.07) 0.316
 E wave deceleration time—ms 208 (54) 198 (49) 10 (− 5 to 26) 0.180
 Mitral annular e′ velocity—cm/sa 11.2 (3.6) 10.3 (3.2) 0.9 (− 1.1 to 1.9) 0.180
 Mitral annular e′/a′  ratioa 1.05 (0.56) 1.12 (0.47) − 0.07 (− 2.20 to 0.14) 0.424
 Mitral E/e′  ratioa 6.68 (2.29) 7.42 (3.04) − 0.74 (− 1.53 to 0.04) 0.162
Right heart
 Right atrial volume—ml 42 (20) 41 (13) 1 (− 3 to 7) 0.192
 Right ventricular diastolic area—cm2 21.8 (4.9) 20.7 (5.3) 1.1 (− 0.4 to 2.6) 0.154
 Right ventricular systolic area—cm2 13.2 (3.9) 12.7 (3.8) 0.5 (− 1.0 to 3.6) 0.167
 Right ventricular fractional area change—% 0.389 (0.125) 0.386 (0.116) 0.030 (− 0.079 to 0.110) 0.224
 Tricuspid annular plane systolic excursion—mm 21.4 (4.0) 22.6 (4.2) − 1.2 (− 2.4 to 0.05) 0.161
 Tricuspid annular peak systolic velocity S′—cm/sa 13.7 (3.0) 13.5 (2.8) 0.2 (− 0.6 to 1.1) 0.570
 Tricuspid regurgitation peak velocity—m/sc 2.28 (0.51) 2.26 (0.50) 0.02 (− 0.24 to 0.28) 0.881
 Tricuspid annular e′ velocity—cm/sa 14.3 (3.7) 13.6 (3.1) 0.7 (0.4 to 1.7) 0.213
 Tricuspid annular e’/a′  ratioa 1.05 (0.54) 0.99 (0.33) 0.06 (− 0.08 to 0.20) 0.408
 Systolic pulmonary artery pressure—mm  Hgc 22 (8) 22 (6) 0 (− 4 to 4) 0.899
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function, and systolic pulmonary arterial pressure were com-
parable in patients who recovered from mild-to-moderate or 
severe COVID-19. Lung ultrasound examination detected 
mild signs of residual pulmonary involvement that were sig-
nificantly greater in patients who had been hospitalized with 
severe COVID-19 than those with mild-to-moderate disease.
Discussion
This study has involved patients who were hospitalized 
with COVID-19 in a University Hospital in North-East 
Italy and had been consecutively recruited, after hospital 
Table 2  Clinical characteristics and laboratory findings of COVID-19 patients with mild-to-moderate and severe disease during hospitalization
Normally distributed values are shown as means (SD). Variables with skewed distribution are shown as medians [interquartile range]. The 95% 
confidence intervals (CI) have not been adjusted for multiple testing and should not be used to infer definitive effects. To convert the values for 
glucose to milligrams per deciliter, divide by 0.0555; to convert the values for creatinine to milligrams per deciliter, divide by 88.434; to convert 
the values for total bilirubin to milligrams per deciliter, divide by 17.104. Glomerular filtration rate was estimated by the Modification of Diet in 
Renal disease (MDRD) formula
a Measurement of serum interleukin 6 was done in 80.8% of patients with mild-to-moderate COVID-19 and 92.6% of patients with severe 











Age—years 56.7 (15.1) 59.7 (11.9) − 3.0 (− 9.4 to 3.3) 0.348
Female sex—no. (%) 42 (54) 7 (26) 28 (6 to 50) 0.012
Body mass index—kg/m2 25.80 (4.97) 27.43 (3.96) − 1.63 (− 3.73 to 0.46) 0.125
Systolic blood pressure—mm Hg 134 (19) 135 (17) − 1.1 (− 10.4 to 8.3) 0.821
Diastolic blood pressure—mm Hg 78 (11) 81 (12) − 2.9 (− 8.5 to 2.7) 0.305
Current smokers—no. (%) 14 (18) 2 (7) 12 (− 2 to 18) 0.231
Hypertension—no. (%) 20 (26) 11 (41) − 15 (− 35 to 5) 0.149
Laboratory findings
 Hemoglobin—g/dl 14.0 (1.2) 14.0 (1.4) 0.0 (− 5.8 to 5.6) 0.971
 White cell count—per  mm3 5812 (2786) 6392 (3442) − 580 (− 1,963 to 803) 0.407
 Lymphocyte count—per  mm3 1041 (418) 748 (326) 275 (88 to 462)  < 0.001
 Platelet count—per  mm3 201,000 (80,000) 208,000 (67,000) − 7000 (− 42,110 to 28,130) 0.396
Glucose—mmol/liter 6.22 (1.50) 6.83 (2.22) − 0.61 (− 1.41 to 0.23) 0.155
Creatinine—mmol/liter 85.8 (24.8) 89.3 (23.9) − 3.5 (− 14.9 to 7.8) 0.532
Glomerular filtration rate—ml/min 78 (21) 78 (17) 0.0 (− 8.9 to 9.2) 0.973
Sodium—mmol/liter 139 (3) 138 (4) 1.0 (− 0.5 to 2.2) 0.232
Potassium—mmol/liter 3.89 (0.42) 3.87 (0.52) 0.02 (− 0.20 to 0.23) 0.924
Alanine aminotransferase—U/liter 20 [13–28] 28 [18–43] − 8 (− 15 to − 2) 0.005
Aspartate aminotransferase—U/liter 24 [19–31] 34 [25–46] − 10 (− 15 to − 3) 0.003
Total bilirubin—mmol/liter 8.21 [7.01–10.52] 8.21 [6.41–11.97] 0.0 (− 1.20 to 2.00) 0.673
Creatine kinase—U/liter 81 [60–118] 118 [69–186] − 37.0 (− 71.0 to 3.0) 0.083
Lactate dehydrogenase—U/liter 422 [345–596] 694 [475–870] − 272 (− 330 to − 101)  < 0.001
C-reactive protein—mg/liter 37.2 [7.1–80.5] 106.1 [49.0–168.5] − 68.9 (− 97.2 to − 20.9)  < 0.001
Procalcitonin—ng/ml 0.05 [0.03–0.10] 0.14 [0.06–0.39] − 0.9 (− 1.4 to − 0.3)  < 0.001
D-dimer—ng/ml 424 [287–757] 1102 [548–2166] − 678 (− 1061 to − 268)  < 0.001
B-type natriuretic peptide—pg/ml 21 [6–47] 25 [14–44] − 4.0 (− 14–0 to 7.0) 0.424
Interleukin 6—pg/mla 18 [8–27] 47 n − 35 (− 62 to − 22)  < 0.001
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discharge, in a short-term follow-up. In these patients, 
cardiac structure and function that were assessed by two-
dimensional, Doppler, and TDI echocardiography did not 
differ from controls who were matched for age, sex, body 
mass index, blood pressure, and major coexisting condi-
tions. Moreover, structural and functional characteristics 
of the heart were comparable in patients who had recov-
ered from mild-to-moderate or severe COVID-19. Despite 
the descriptive nature of this study due to its observational 
design, these echocardiographic findings together with 
normality of serum troponin, strongly suggest that patients 
who recover from COVID-19 do not have considerable 
pathological sequelae in the heart.
There is now considerable interest in the identification 
of persistent organ damage in survivors of COVID-19. This 
topic has ended up in the spotlight after demonstration of 
a pathological involvement of many organs different from 
the lung during the acute phase of infection [3]. Cardiac 
injury has been identified by detection of increased markers 
of myocardial damage during the critical stage of COVID-19 
[17] and has been associated with an increased risk of death 
[6, 7]. Anecdotal necropsy studies conducted in subjects who 
died with COVID-19 have identified myocardial infiltration 
by interstitial mononuclear inflammatory cells, suggesting 
existence of a SARS-CoV-2-related myocarditis [18, 19]. 
Also, isolated cases of severe myocarditis with biventricular 
dysfunction have been reported in patients with COVID-19 
[20, 21], even in the absence of overt pulmonary disease 
[22]. Although position statements of scientific societies 
have suggested use of targeted echocardiography for cardiac 
screening of patients with COVID-19 [13, 23], information 
obtained in the acute phase of illness is limited to a few 
studies. Right ventricular dilatation and reduced right ven-
tricular fractional area change were observed in 27% of 74 
patients with COVID-19 pneumonia and increased troponin 
levels, suggesting right ventricular systolic dysfunction as a 
possible consequence of acute pulmonary arterial hyperten-
sion [24]. Signs of pulmonary hypertension were observed 
with use of cardiac ultrasound in another investigation of 
112 COVID-19 patients [25]. In a more recent systematic 
echocardiographic study conducted within 24 h of hospi-
tal admission in 100 COVID-19 patients, right ventricular 
dilatation and dysfunction have been reported in 39% of 
patients, left ventricular diastolic dysfunction in 16%, and 
left ventricular systolic dysfunction in 10% [26]. Thus, evi-
dence obtained in the acute phase of COVID-19 has consist-
ently and prevalently indicated a functional involvement of 
the right ventricle in a substantial proportion of patients. In 
this context, right ventricular dysfunction could be due to 
a hemodynamic overload caused by an increased pulmo-
nary arterial pressure that, in turn, results from pulmonary 
thromboembolism.
Pulmonary thromboembolism has been demonstrated in 
patients who died with COVID-19 pneumonia as a possible 
consequence of a COVID-19 induced prothrombotic state 
[27]. The presence of a prothrombotic state in COVID-19 
patients has also been supported by frequent detection of 
markedly increased D-dimer levels [28], and therefore, 
specific attention should be directed to assessment of right 
ventricular function even after recovery from infection. 
In this study, both right ventricular function and systolic 
pulmonary arterial pressure did not differ in patients who 
Table 3  Clinical and 
electrocardiographic 
characteristics of COVID-19 
patients with mild-to-moderate 






Fever (> 37.5 °C)—no. (%) 3 (4) 1 (4)
Dyspnea—no. (%) 4 (5) 1 (4)
Cough—no. (%) 3 (4) 1 (4)
Chest pain—no. (%) 3 (4) 2 (7)
Fatigue—no. (%) 5 (6) 2 (7)
Gastrointestinal—no. (%) 2 (3) 0 (0)
Neurological—no. (%) 5 (6) 1 (4)
Dysgeusia/anosmia—% 7 (9) 2 (7)
Normal sinus rhythm—no. (%) 72 (92) 24 (89)
Atrial fibrillation/flutter—no. (%) 6 (8) 3 (11)
PQ-segment > 0.20 s—no. (%) 6 (8) 2 (7)
Right bundle-branch block—no. (%) 6 (8) 3 (11)
Left bundle-branch block—no. (%) 1 (1) 0 (0)
ST-segment elevation/depression—no. (%) 5 (6) 1 (4)
T-wave abnormalities—no. (%) 10 (13) 4 (15)
Long QTc—no. (%) 1 (1) 0 (0)
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recovered from COVID-19 and controls. Also and most 
important, no significant abnormalities in right ventricular 
function and systolic pulmonary arterial pressure were found 
despite detection of persistent pulmonary involvement in 
COVID-19 patients who had been hospitalized with severe 
illness. These observations strongly suggest that cardiac 
changes that are associated with pulmonary involvement of 
COVID-19 during the acute phase of infection are rapidly 
reversed after recovery from disease.
More recently, two cross-sectional magnetic resonance 
studies have examined the heart of COVID-19 survivors 
in the early recovery phase. Puntmann et al. reported on 
100 COVID patients who recovered from infection and 
had a cardiac magnetic resonance scan a mean of 71 days 
Table 4  Cardiac and lung ultrasound characteristics of COVID-19 patients with mild-to-moderate and severe disease at follow-up
Values are means (SD). The 95% confidence intervals (CI) have not been adjusted for multiple testing and should not be used to infer definitive 
effects
a Tissue-Doppler imaging variables. S’, peak systolic velocities were measured either at the mitral or tricuspid annulus with the Doppler beam 
directed parallel to the myocardial walls; e’, early-diastolic myocardial velocity was measured either at the mitral or tricuspid annulus; a’, late-
diastolic myocardial velocity was measured either at the mitral or tricuspid annulus
b E, early-wave trans-mitral peak velocity; A, late-wave trans-mitral peak velocity
c Measurement of tricuspid regurgitation peak velocity and calculation of systolic arterial pulmonary pressure could be performed in 84.6% of 








Difference (95% CI) P value
Left heart
 Left atrial volume—ml 42 (20) 42 (17) − 0.0 (− 9 to 8) 0.914
 Left ventricular end-diastolic diameter—mm 47 (6) 47 (6) 0.0 (− 3.1 to 2.5) 0.807
 Left ventricular end-systolic diameter—mm 29 (6) 27 (5) − 2.0 (− 1.2 to 3.8) 0.299
 Interventricular septum—mm 9.1 (2.0) 9.2 (1.4) − 0.1 (− 1.1 to 0.6) 0.612
 Posterior wall—mm 9.0 (2.0) 9.2 (1.4) − 0.2 (− 1.0 to 0.7) 0.723
 Left ventricular mass index—g/m2.7 34.5 (10.9) 35.2 (10.2) − 0.7 (− 5.5 to 4.1) 0.775
 Relative wall thickness—% 0.385 (0.105) 0.391 (0.078) − 0.006 (− 0.048 to 0.039) 0.829
 Left ventricular ejection fraction—% 68 (10) 69 (8) − 2 (− 6 to 3) 0.409
 Left ventricular fractional shortening—% 38.5 (7.2) 41.1 (6.3) − 2.6 (− 6.0 to 0.8) 0.128
 Mitral annular plane systolic excursion—mm 13.0 (2.5) 12.5 (1.9) 0.5 (− 0.6 to 1.6) 0.377
 Mitral annular peak systolic velocity S’—cm/sa 9.2 (2.0) 9.5 (1.7) − 0.3 (− 1.1 to 0.5) 0.479
 Peak E wave velocity—cm/s 76 (21) 70 (16) 6.0 (− 2.4 to 15.3) 0.153
 E/A  ratiob 1.29 (0.58) 1.14 (0.41) 0.16 (− 0.10 to 0.41) 0.223
 E wave deceleration time—ms 207 (56) 210 (47) − 3 (− 27 to 21) 0.809
 Mitral annular e’ velocity—cm/sa 11.4 (3.3) 10.3 (2.1) 1.1 (− 0.3 to 2.5) 0.123
 Mitral annular e’/a’  ratioa 1.13 (0.56) 1.00 (0.40) 0.13 (− 0.11 to 0.36) 0.279
 Mitral E/e’  ratioa 6.63 (2.25) 7.22 (2.21) − 0.59 (− 1.61 to 0.42) 0.252
Right heart
 Right atrial volume—ml 42 (21) 42 (14) − 0 (− 9 to 9) 0.930
 Right ventricular diastolic area—cm2 21.5 (5.1) 22.5 (4.7) − 1.0 (− 3.1 to 1.3) 0.410
 Right ventricular systolic area—cm2 13.1 (4.0) 13.6 (3.6) − 0.5 (− 2.2 to 1.3) 0.586
 Right ventricular fractional area change—% 0.389 (0.123) 0.391 (0.134) − 0.002 (− 0.058 to 0.054) 0.939
 Tricuspid annular plane systolic excursion—mm 21.7 (3.6) 20.6 (5.0) 1.1 (− 0.7 to 3.0) 0.219
 Tricuspid annular peak systolic velocity S’—cm/sa 13.8 (3.0) 13.7 (2.9) 0.1 (− 1.3 to 1.3) 0.973
 Tricuspid regurgitation peak velocity—m/sc 2.37 (0.40) 2.18 (0.48) 0.19 (− 0.04 to 0.42) 0.109
 Tricuspid annular e’ velocity—cm/sa 14.6 (3.7) 13.3 (3.5) 1.3 (− 0.3 to 3.0) 0.100
 Tricuspid annular e’/a’  ratioa 1.09 (0.59) 0.90 (0.37) 0.20 (− 0.06 to 0.44) 0.127
 Systolic pulmonary artery pressure—mm  Hgc 23 (7) 21 (9) 2 (− 1 to 8) 0.120
Lung ultrasound
 Score 1.0 (1.7) 3.7 (3.6) − 2.7 (− 3.8 to − 1.8)  < 0.001
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after diagnosis [29]. These subjects had larger left ven-
tricular volumes and lower ejection fraction compared to 
controls, and 60% had evidence of ongoing myocardial 
inflammation. Another study by Rajpal et al. reported on 
26 young athletes who recovered from COVID-19 and had 
a cardiac magnetic resonance from 11 to 53 days after 
diagnosis [30]. Of these patients, four had imaging data 
suggestive of myocarditis and eight of possible prior myo-
cardial injury. Both these studies reported changes of the 
left ventricle, whereas, as indicated above, most magnetic 
resonance data obtained during the acute phase of COVID-
19 reported involvement of the right ventricle. To notice, 
more than two-thirds of patients included in Puntmann’s 
paper were not hospitalized during the acute phase of 
COVID-19 and patients included in Rajpal’ s study were 
asymptomatic or mildly symptomatic, which suggests that 
their clinical conditions at presentation were not severe. 
This observation raises an important question on what 
could be the meaning, in terms of clinical relevance, of 
cardiac changes that were detected by magnetic resonance 
imaging in these patients. It would be definitely difficult 
to reconcile all these findings, because cardiac changes in 
people who recover from COVID-19 appear to be highly 
variable and this might depend on the technique that is 
used, the characteristics of patients in terms of severity of 
disease, and timing of examination. In particular, cardiac 
findings might differ significantly from the acute phase of 
infection and the short-term and long-term recovery phase 
and this is why it will be important to monitor the cardiac 
conditions of COVID-19 survivors even in a long-term 
follow-up.
Because cardiac abnormalities may persist in COVID-19 
patients after viral clearance is achieved, or even arise in 
the chronic phase of disease, evaluation of cardiac struc-
ture and function in patients who recover from clinically 
relevant illness is of great importance. The present study 
was conducted during the pandemic peak in a geographic 
area of northeast Italy that has faced a slightly lower burden 
of infectivity, morbidity, and mortality than other regions 
in this country. However, during the study period mortal-
ity among COVID-19 patients who were admitted to our 
hospital with severe illness was 55%. Notably, the charac-
teristics of patients included in our analysis overlap those 
that have been reported in much larger case series of patients 
with COVID-19 [31]. Consistent with previous descriptions 
of disease, our patients with severe COVID-19 were more 
frequently males, had lower lymphocyte count, and higher 
serum values of C-reactive protein, lactate dehydrogenase, 
procalcitonin, D-dimer, and interleukin 6 than patients with 
mild-to-moderate COVID-19 [2]. Therefore, despite the 
important limitation due to the small size of our study, these 
findings could be reasonably generalized to all subjects that 
recover from COVID-19.
Additional limitations of our study should be highlighted. 
First, lack of echocardiographic measurements obtained dur-
ing the hospital stay in the acute phase of COVID-19 does 
not allow any longitudinal assessment of cardiac changes. 
Second, inclusion of consecutive COVID-19 patients who 
attended the follow-up visits might have led to a selection 
bias that occurs almost inevitably in observational studies. 
Third, although the matching process of control subjects 
was accurate for demographic and clinical variables, uncon-
trolled confounders might have affected the final results. For 
instance, significant differences in the frequency of use of 
antivirals and interleukin-6 antagonists between patients 
with mild-to-moderate and severe COVID-19 could have 
affected the cardiac outcome. Last, because data were col-
lected after a median of 6 weeks after COVID-19 diagnosis, 
these do not provide information on the cardiac outcome of 
infection in a longer time span.
In conclusion, in this study we did not identify struc-
tural or functional abnormalities in the heart of survivors 
of COVID-19 more than a month after the first detection of 
infection. No abnormalities were also observed in the heart 
of patients who recovered from severe COVID-19. These 
findings suggest that patients who recover from COVID-19 
do not have considerable cardiac sequelae, but this evidence 
needs to be further investigated in larger and longer-term 
studies.
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